A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Stopped The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns
Conditions
- Peripheral T Cell Lymphoma
- Diffuse Large B-cell Lymphoma
- Classical Hodgkin Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Non-Small Cell Lung Cancer
Interventions
- DRUG: PF-08046032
- DRUG: Sasanlimab
Sponsor
Pfizer